GURU.Markets stock price, segment price, and overall market index valuation
The company's share price APTO
Aptose is a biotech company focused on treating blood cancer. Its stock price is volatile and dependent on clinical trial results. The chart reflects investor confidence in the potential of its targeted therapies to address unmet medical needs.
Share prices of companies in the market segment - Cancer blood
Aptose Biosciences is a biopharmaceutical company focused on developing targeted therapies for the treatment of blood cancers, specifically acute myeloid leukemia. We've categorized it as "Blood Cancer." The chart below shows how investors view the prospects of companies in this complex field.
Broad Market Index - GURU.Markets
Aptose Biosciences is a Canadian biopharmaceutical company developing targeted therapies for the treatment of blood cancers. As a component of the GURU.Markets index, it represents the biotech sector. The chart below shows the US market. See how this company's stock compares to the US market.
Change in the price of a company, segment, and market as a whole per day
APTO - Daily change in the company's share price APTO
Aptose Biosciences Inc.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its blood cancer treatments.
Daily change in the price of a set of shares in a market segment - Cancer blood
Aptose Biosciences is a biopharmaceutical company developing targeted therapies for the treatment of blood cancers. Oncology, particularly hematology, is a highly volatile sector. The chart below reflects average fluctuations in this industry, providing context for assessing the risks and potential of Aptose shares.
Daily change in the price of a broad market stock, index - GURU.Markets
Aptose Biosciences is a biotech company developing cell therapy for blood cancer. Its shares are a bet on a scientific breakthrough in medicine. Their high volatility, driven by research results, contributes to the dynamics of the entire innovative market sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization APTO
Aptose Biosciences Inc.'s year-over-year performance is a story about the development of its targeted drugs for the treatment of blood cancers. Its 12-month market capitalization is entirely dependent on clinical trial data. Positive results for its kinase inhibitors could offer new hope for patients with acute myeloid leukemia.
Annual dynamics of market capitalization of the market segment - Cancer blood
As an early-stage biotech, Aptose is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its blood cancer drugs. Its stock price will reflect investors' speculative belief in its potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aptose Biosciences, a clinical-stage biotech focused on treating blood cancer, is a high-risk but potentially high-return asset. Its annual market capitalization performance is completely disconnected from macroeconomics and is determined solely by clinical trial data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization APTO
Aptose is a clinical-stage oncology company focused on blood cancer. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its targeted drugs, presented at conferences, has generated strong reactions.
Monthly dynamics of market capitalization of the market segment - Cancer blood
Aptose Biosciences is a biotech company focused on developing targeted therapies for the treatment of blood cancers. This segment of oncology is one of the fastest-growing. The chart below reflects how investor sentiment has changed regarding innovative approaches to treating leukemia and lymphoma, often in response to clinical trial data.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aptose Biosciences is a clinical-stage biotech company focused on treating blood cancer. Its stock represents a high-risk bet on the success of its scientific developments. Its performance will be determined entirely by news about clinical trials, not by overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization APTO
Shares of Aptose Biosciences, a clinical-stage oncology company, are extremely volatile. Weekly price movements depend entirely on news about the progress of clinical trials of their targeted drugs for blood cancer. The chart below is a prime example of how short-term scientific data shapes value in innovative medicine.
Weekly dynamics of market capitalization of the market segment - Cancer blood
Aptose Biosciences is a biotech company specializing in blood cancer treatment. Its shares move in sync with clinical trial news. The chart clearly demonstrates how its performance is detached from the market and driven by scientific data rather than general trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Aptose Biosciences is a biotech company whose fate depends on scientific data. This chart clearly demonstrates how out of sync its weekly performance can be with the broader market. A single clinical trial announcement can cause massive swings while the S&P 500 remains stagnant.
Market capitalization of the company, segment and market as a whole
APTO - Market capitalization of the company APTO
The price chart of Aptose Biosciences Inc. reflects its long-standing efforts to develop targeted drugs for the treatment of blood cancer. This clinical-stage biotech company's market cap depends on its research results. This trend illustrates the long and arduous journey of drug development in oncology.
APTO - Share of the company's market capitalization APTO within the market segment - Cancer blood
Aptose Biosciences' market share in oncology reflects its focus on developing targeted drugs for the treatment of blood cancers. Its market share reflects its portfolio of molecules that target key tumor cell survival mechanisms, making it an attractive player in this competitive field.
Market capitalization of the market segment - Cancer blood
Here's a chart of the total market capitalization of biotech companies developing targeted therapies for blood cancer. Aptose Biosciences is one of the players in this field. The chart's dynamics reflect the high volatility and risks associated with clinical trials in this complex field.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes hope for patients with acute leukemia. Aptose Biosciences' market cap is a valuation of its targeted drug portfolio. The line shows the roller coaster of clinical trials and investor confidence in the company's ability to carve out a market share in the challenging oncology market.
Book value capitalization of the company, segment and market as a whole
APTO - Book value capitalization of the company APTO
Aptose Biosciences' book value represents its scientific capital. The chart below reflects the valuation of its pipeline of developments targeting hematological malignancies (blood cancers). The line's growth signals success in clinical trials, which are the biotech company's core asset.
APTO - Share of the company's book capitalization APTO within the market segment - Cancer blood
Aptose Biosciences' core assets are its laboratories developing targeted therapies for blood cancer. The chart shows the company's share of this cutting-edge scientific infrastructure, which forms the physical foundation for its innovative oncology programs.
Market segment balance sheet capitalization - Cancer blood
Biotechnology is a world of contrasts. The graph shows the massive factories of pharmaceutical giants. Aptose Biosciences, as a development company, has a more streamlined model. Its value lies in its intellectual property, not in the scale of production that is typical of the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
Aptose Biosciences is a biotechnology company developing targeted therapies for the treatment of blood cancers. Its assets include a portfolio of promising molecules and clinical trial data. The chart shows the financial resources dedicated to the fight against leukemia and lymphoma.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - APTO
Aptose Biosciences is a biotech company focused on treating blood cancer. Its book value is derived from cash flow for research. The chart below visualizes the hopes and risks. The company's future will be determined entirely by the results of clinical trials.
Market to book capitalization ratio in a market segment - Cancer blood
Aptose Biosciences Inc. is a biotech company developing targeted therapies for blood cancer. Its value depends entirely on the success of its drugs in clinical trials. This chart shows how its market valuation is a bet on the future and is significantly disconnected from its current assets.
Market to book capitalization ratio for the market as a whole
Aptose Biosciences is a biopharmaceutical company developing targeted therapies for the treatment of blood cancers. The market valuation shown in this chart is based on the potential of their development pipeline. The dynamics reflect news about clinical trials.
Debts of the company, segment and market as a whole
APTO - Company debts APTO
Aptose Biosciences, a clinical-stage biotech focused on treating blood cancer, uses raised capital to fund its R&D programs. This chart shows how the company spends funds on clinical trials of its targeted drugs, a long and risky process.
Market segment debts - Cancer blood
Aptose Biosciences is a clinical-stage biotech company focused on treating blood cancer. This chart shows how its debt policy (or lack thereof) reflects the high risk of its developments and its reliance on equity capital to fund expensive clinical trials of its targeted therapies.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio APTO
ARC Document Solutions provides document and print management services, primarily for the architectural and construction industries. This chart shows the company's financial structure as it adapts to the industry's digitalization, which requires investment in new technologies while potentially reducing demand for traditional services.
Market segment debt to market segment book capitalization - Cancer blood
Aptose Biosciences is a clinical-stage biotech company focused on developing targeted therapies for blood cancers, specifically acute myeloid leukemia. This chart compares its debt load to the overall market capitalization of the oncology sector. It shows how the company funds its research.
Debt to book value of all companies in the market
Aptose Biosciences is a clinical-stage biotech company focused on treating blood cancers. Research failures are common in this sector. This graph of total market debt shows the market's risk appetite, which directly impacts Aptose's ability to attract new funding to continue its research programs after receiving mixed results.
P/E of the company, segment and market as a whole
P/E - APTO
For Aptose Biosciences, a clinical-stage oncology company, the P/E ratio is not applicable. The company has no profit, and its valuation on this chart is arbitrary. The actual value is a speculative bet on the success of its clinical trials and the potential of future blood cancer drugs.
P/E of the market segment - Cancer blood
Aptose Biosciences is a clinical-stage biotech company developing targeted therapies for the treatment of hematological malignancies, such as acute myeloid leukemia. This chart shows the average valuation for the oncology sector, reflecting how investors assess the risks and potential of smaller companies working on blood cancer treatments.
P/E of the market as a whole
Aptose Biosciences is a clinical-stage biopharmaceutical company developing targeted therapies for the treatment of hematological malignancies, such as acute myeloid leukemia. This risk appetite chart helps understand how investors value biotech companies in the oncology field.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company APTO
Aptose Biosciences is a biopharmaceutical company developing targeted therapies for the treatment of blood cancers, particularly acute myeloid leukemia. This graph reflects market expectations for the success of its clinical programs. Future revenue depends on trial results and approval.
%20P%2FE%20APTO&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-APTO&v=1772520342324 "Chart of the company's future (projected) P/E APTO")
Future (projected) P/E of the market segment - Cancer blood
Aptose Biosciences is a clinical-stage biotech company focused on developing targeted therapies for the treatment of blood cancer. This chart is a measure of market expectations, showing how investors assess the scientific potential of its developments compared to other oncology startups.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-blood&v=1772520342362 "Future (projected) P/E graph of the market segment - Cancer blood")
Future (projected) P/E of the market as a whole
Aptose Biosciences is a clinical-stage biotech company focused on developing targeted therapies for blood cancer. Its future depends entirely on the results of clinical trials. This chart, reflecting market optimism, demonstrates the investor appetite for risk, which is necessary to fund long-term and risky oncology research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772520342393 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit APTO
Aptose Biosciences is a clinical-stage biotechnology company specializing in the development of targeted therapies for the treatment of blood cancers. Its financial performance is driven by R&D expenses. This chart illustrates the significant investments required to develop innovative oncology drugs and advance them through clinical trials.
Profit of companies in the market segment - Cancer blood
Aptose Biosciences is a biotechnology company specializing in the development of targeted therapies for the treatment of blood cancers, particularly acute myeloid leukemia. This chart, showing overall sector profitability, reflects the company's continued pursuit of new treatments. Success in Aptose's clinical programs could offer hope to patients and have a significant impact on the entire industry.
Overall market profit
Aptose Biosciences is a biotechnology company focused on developing targeted therapies for the treatment of blood cancers such as leukemia. Its approach is to create drugs that overcome resistance to existing therapies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company APTO
Aptose Biosciences is a biotechnology company developing targeted therapies for the treatment of blood cancers. Future revenue projections are speculative and depend entirely on the results of clinical trials.
%20profit%20of%20the%20company%20APTO&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-APTO&v=1772520342431 "Graph of future (projected) profit of the company APTO")
Future (predicted) profit of companies in the market segment - Cancer blood
Aptose Biosciences is a biopharmaceutical company developing targeted therapies for the treatment of hematological malignancies, such as leukemia. This chart shows future revenue expectations for the entire blood cancer segment. It allows one to assess the potential of the company's developments against the overall outlook for this competitive field of oncology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-blood&v=1772520342437 "Graph of future (predicted) profits of companies in a market segment - Cancer blood")
Future (predicted) profit of the market as a whole
Aptose Biosciences is a biotech company focused on treating blood cancer. Its success depends on the results of clinical trials. This chart, reflecting investor risk appetite, is of great importance to Aptose. Positive economic forecasts facilitate raising the capital needed to continue expensive research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772520342438 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - APTO
Aptose Biosciences is a clinical-stage biotech company specializing in the development of targeted therapies for the treatment of blood cancer. For such a company, this chart is a measure of investor hope. It reflects a valuation based on the potential of its scientific developments, not on current sales revenue.
P/S market segment - Cancer blood
Aptose Biosciences Inc. is a biotechnology company specializing in the development of targeted therapies for the treatment of hematological malignancies (blood cancers). This chart shows how investors value the oncology sector's revenue, demonstrating the level of expectations for clinical development and the scientific potential of Aptose's pipeline.
P/S of the market as a whole
Aptose Biosciences is a clinical-stage biopharmaceutical company focused on developing targeted therapies for the treatment of hematological malignancies, such as acute myeloid leukemia. This chart, reflecting the average valuation, demonstrates how biotech companies' valuations are influenced by future potential.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company APTO
Aptose Biosciences is a clinical-stage biotechnology company developing targeted therapies for the treatment of blood cancers. This chart shows the market's assessment of its potential future revenue. It reflects investor confidence in the success of its clinical programs and the commercial potential of its innovative oncology therapies.
%20P%2FS%20APTO&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-APTO&v=1772520342520 "The graph of the company's future (projected) P/S APTO")
Future (projected) P/S of the market segment - Cancer blood
Aptose Biosciences is a clinical-stage biotechnology company developing targeted therapies for the treatment of blood cancers, specifically acute myeloid leukemia. This chart shows the median estimated future revenue in the blood cancer sector. It helps understand how investors view Aptose's research and development potential in this complex area of oncology.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20blood&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-blood&v=1772520342525 "Future (projected) P/S market segment graph - Cancer blood")
Future (projected) P/S of the market as a whole
Aptose Biosciences (APTO) is a clinical-stage biotech company developing targeted therapies for the treatment of blood cancers. Their future depends solely on the results of clinical trials. This graph of general economic expectations has no bearing on their scientific developments in the field of oncology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772520342536 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales APTO
Aptose Biosciences is a clinical-stage biotech company specializing in the treatment of blood cancer. It has no sales revenue. Its financial history consists of investments in the development of targeted therapies. The graph will reflect future revenue from licensing or partnerships for its drug candidates following successful trials.
Sales of companies in the market segment - Cancer blood
Aptose Biosciences is a clinical-stage oncology company focused on developing targeted therapies for the treatment of blood cancers, particularly acute myeloid leukemia. It currently has no sales revenue. Its future revenue depends on the success of its innovative drugs.
Overall market sales
Aptose Biosciences Inc. is a biotechnology company specializing in the development of targeted therapies for the treatment of blood cancer. Its success depends entirely on the results of clinical trials. The overall economic situation, reflected in this chart, influences the investment climate in biotech and the ability to attract capital to finance expensive R&D projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company APTO
Aptose Biosciences is a clinical-stage biotechnology company developing targeted therapies for the treatment of blood cancers, particularly acute myeloid leukemia. This chart reflects analysts' long-term expectations for its research pipeline.
%20sales%20of%20the%20company%20APTO&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-APTO&v=1772520342582 "Schedule of future (projected) sales of the company APTO")
Future (projected) sales of companies in the market segment - Cancer blood
Aptose Biosciences is a biotechnology company developing targeted therapies for the treatment of blood cancers, specifically acute myeloid leukemia. This chart shows the outlook for the blood cancer sector, reflecting the urgent need for new treatments for patients with relapsed or refractory forms of the disease.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-blood&v=1772520342584 "Schedule of future (projected) sales of companies in the market segment - Cancer blood")
Future (projected) sales of the market as a whole
The biotech investment climate, illustrated by this chart, is important for Aptose Biosciences. The company is developing targeted therapies for blood cancer. Its ability to fund lengthy and expensive clinical trials is directly dependent on the influx of capital into the industry, which increases with economic growth.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772520342586 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality APTO
Aptose Biosciences is a clinical-stage biotechnology company developing targeted therapies for the treatment of blood cancers. This chart reflects its investment in research. Future profitability is entirely dependent on the success of clinical trials and the commercialization of its innovative oral therapies.
Market segment marginality - Cancer blood
Aptose Biosciences is a biopharmaceutical company developing targeted therapies for the treatment of blood cancers, such as acute myeloid leukemia. Profitability depends on the success of its clinical programs. This chart shows the average profitability in the pharmaceutical industry. It provides context for assessing the potential of its innovative approaches to treating hematological malignancies.
Market marginality as a whole
Aptose Biosciences is a clinical-stage biotech company developing targeted therapies for blood cancer. Its future depends entirely on the results of clinical trials and its ability to raise capital. This chart reflects the overall risk appetite of investors, which determines the availability of funding for such long-term and risky scientific projects.
Employees in the company, segment and market as a whole
Number of employees in the company APTO
Aptose Biosciences Inc. is a biotechnology company developing targeted drugs for the treatment of blood cancers. This graph shows a compact team of scientists and clinicians. A small staff is typical for clinical-stage companies, where the primary goal is to prove the efficacy and safety of their drug candidates.
Share of the company's employees APTO within the market segment - Cancer blood
Aptose Biosciences is a biotechnology company focused on developing targeted therapies for the treatment of blood cancers, specifically acute myeloid leukemia. This chart shows the company's share of the total number of scientists in this specialized field. This reflects its scientific potential and focus on solving complex oncological problems.
Number of employees in the market segment - Cancer blood
Aptose Biosciences Inc. is a biopharmaceutical company developing targeted therapies for the treatment of hematological malignancies, such as acute myeloid leukemia. This chart, showing employment in the blood cancer sector, is important. The growing number of scientists in this field indicates an intensive search for new treatments for patients with poor prognosis.
Number of employees in the market as a whole
Aptose Biosciences is a biotech company focused on treating blood cancer. Drug development in this area requires significant investment. This overall employment chart reflects the health of the financial system. During periods of economic growth, investors are more inclined to fund long-term, risky, but potentially breakthrough projects in oncology.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company APTO (APTO)
Aptose Biosciences (APTO) is a biopharmaceutical company specializing in the treatment of blood cancer (leukemia). It's a classic R&D company. The company's market value is a bet on the success of their clinical trials. This chart reflects the high valuation of their "intellectual capital" (patents) for their small staff of scientists.
%20of%20the%20company%20APTO%20(APTO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-APTO-APTO&v=1772520342749 "Chart of market capitalization per employee (in thousands of dollars) of the company APTO (APTO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer blood
Aptose Biosciences is a biotech company focused on treating blood cancer. Its market cap is based on clinical trial expectations. This metric clearly demonstrates that in biotech, investors value not current operations but the scientific breakthrough that can be achieved by a small team of researchers.
%20by%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-blood&v=1772520342756 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer blood")
Market capitalization per employee (in thousands of dollars) for the overall market
Aptose Biosciences is a clinical-stage biotech company developing targeted therapies for blood cancer. Its market cap is based on its scientific potential. This chart shows the typical high valuation per employee for biotech, where investors are betting on the future success of a small but focused scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772520342786 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company APTO (APTO)
Aptose Biosciences is a clinical-stage biotech company focused on developing targeted drugs for the treatment of blood cancer (leukemia). This is pure R&D. This chart shows the company's "burn rate": how much the company spends (negative profit) on each of its scientists to advance drug candidates through clinical trials.
%20Chart%20APTO%20(APTO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-APTO-APTO&v=1772520342828 "Company Profit Per Employee (in thousands of dollars) Chart APTO (APTO)")
Profit per employee (in thousands of dollars) in the market segment - Cancer blood
Aptose Biosciences is a biotech company specializing in the development of targeted therapies for the treatment of blood cancers. While in clinical trials, the company incurs significant research expenses. This chart helps evaluate the effectiveness of managing these expenses while awaiting results that could lead to partnerships or commercialization.
%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-blood&v=1772520342845 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer blood")
Profit per employee (in thousands of dollars) for the market as a whole
Aptose Biosciences (APTO) is a biopharmaceutical company developing targeted therapies for the treatment of blood cancer (leukemia). It is a clinical-stage R&D company with no profit. This metric is negative and reflects the "cost" of a single scientist working in the complex field of hematology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772520342888 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee APTO (APTO)
Aptose Biosciences is a biotech company developing drugs to treat blood cancer. While in clinical trials, it may not generate sales revenue. This graph is important as a benchmark for assessing the future commercial potential of their developments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-APTO-APTO&v=1772520342912 "Sales chart per company employee APTO (APTO)")
Sales per employee in the market segment - Cancer blood
Aptose Biosciences is a clinical-stage biotech company developing targeted therapies for blood cancers (such as AML). This is an R&D business. This chart clearly shows that the company has no commercial revenue. The productivity of their research team is measured solely by progress in clinical trials.
Sales per employee for the market as a whole
Innovex International (INVX) (likely a SPAC or recent listing) – based on past performance, the company may be in the technology or consumer goods industries. Without a clear business profile, it's difficult to provide a precise analysis. However, this chart is a general guide: it will show whether the business is scalable (high revenue per employee, like software) or labor-intensive (low revenue, like services).
Short shares by company, segment and market as a whole
Shares shorted by company APTO (APTO)
Aptose Biosciences (APTO) is a clinical-stage biotech focused on blood cancer. This chart tracks bearish bets. Shorts reflect the high risk of clinical trial failure, which is typical for this sector.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-APTO-APTO&v=1772520342976 "Short Shares Chart for the Company APTO (APTO)")
Shares shorted by market segment - Cancer blood
Aptose (APTO) is a biotech company developing targeted therapies for the treatment of blood cancers, particularly acute myeloid leukemia. The chart below represents the overall short position in the oncology biotech sector. It reflects the skepticism investors have about the success of early-stage developments.
Shares shorted by the overall market
Aptose (APTO) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing APTO won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator APTO (APTO)
This chart for Aptose is a barometer of hope in the treatment of blood cancer (AML). The company develops targeted therapies. "Overheating" (above 70) occurs due to encouraging early clinical trial data. A failure to achieve remission in patients or drug toxicity immediately plunges the stock into "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-APTO-APTO&v=1772520343054 "RSI 14 indicator chart for the company's stock APTO (APTO)")
RSI 14 Market Segment - Cancer blood
Aptose is a Canadian biotech company focused on blood cancer. They focus on small molecules (kinase inhibitors) for the treatment of leukemia and lymphoma. The blood cancer (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of the entire segment. It helps us understand: is Aptose's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Aptose Biosciences (APTO) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast APTO (APTO)
Aptose Biosciences is a biotech company focused on developing targeted therapies for blood cancers, specifically AML. This chart shows the average 12-month analyst forecast, representing their collective speculative bet on the success of clinical trials and approval of their drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-APTO-APTO&v=1772520343105 "A chart showing analyst consensus forecasts for the expected stock price. APTO (APTO)")
The difference between the consensus estimate and the actual stock price APTO (APTO)
Aptose (APTO) is a biotech company focused on developing targeted therapies for the treatment of difficult-to-treat blood cancers (AML). This chart shows how the current share price differs from its "fair" value. It reflects analysts' "venture capital" assessment of their R&D portfolio and the likelihood of clinical success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-APTO-APTO&v=1772520343146 "A chart showing the difference between the consensus forecast and the actual stock price. APTO (APTO)")
Analyst consensus forecast for stock prices by market segment - Cancer blood
Aptose (APTO) is a clinical-stage biotech company developing targeted drugs for the treatment of blood cancer (leukemia). This is high-risk R&D. This chart shows analysts' overall expectations for the blood cancer sector. It reflects whether experts believe breakthroughs in leukemia treatment are possible.
Analysts' consensus forecast for the overall market share price
Aptose Biosciences (APTO) is a clinical-stage biopharmaceutical company focused on treating blood cancer (leukemia). This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market. It is a clear indicator of the "open" or "closed" funding window for speculative biotechs seeking capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index APTO
Aptose is a biotech R&D company focused on blood. Their R&D pipeline (targeted inhibitors) is focused on new treatment mechanisms for blood cancers (leukemia, lymphoma), particularly for resistant patients. This chart is purely an R&D barometer. It doesn't reflect revenue, but rather a speculative estimate of their (very risky) pipeline and their clinical trial data.
AKIMA Market Segment Index - Cancer blood
Aptose Biosciences is an oncology biotech focused on blood cancers (leukemia, lymphoma). They develop small molecules to attack cancer cells that have become resistant to therapy. This chart compares their composite index to the sector, showing how their last-resort approach compares to others.
The AKIM Index for the overall market
Aptose Biosciences is a biotech company developing precision drugs for the treatment of acute myeloid leukemia (AML). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this scientific company, struggling for survival and success, fits into the context of overall economic trends.
